Free tool
FAERS Monitor: Repatha
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125522 or its brand name (Repatha, Evolocumab). Reports on generic versions are filed under their own applications.
Reports
165,049
Serious
28,672
17% of reports
Hospitalization
9,006
Death reported
2,144
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device difficult to use33,254
- drug dose omission by device24,856
- wrong technique in product usage process22,690
- accidental exposure to product17,173
- injection site pain11,254
- product storage error6,709
- back pain5,658
- myalgia5,484
- injection site bruising4,954
- drug dose omission4,929
- device use error4,408
- fatigue4,161
- arthralgia4,143
- injection site haemorrhage4,136
- off label use3,997
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 13 |
| 2015 | 801 |
| 2016 | 6,377 |
| 2017 | 20,201 |
| 2018 | 28,249 |
| 2019 | 9,722 |
| 2020 | 8,999 |
| 2021 | 10,476 |
| 2022 | 12,351 |
| 2023 | 24,562 |
| 2024 | 25,531 |
| 2025 | 7,912 |
| 2026 | 9,852 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,889,110 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device difficult to useSignal | 33,254 | 127.5 | 125.7 | 2,085,871 |
| drug dose omission by deviceSignal | 24,856 | 58.8 | 57.9 | 967,457 |
| accidental exposure to productSignal | 17,173 | 25.3 | 24.9 | 335,384 |
| device use errorSignal | 4,408 | 18.4 | 17.8 | 63,301 |
| wrong technique in product usage processSignal | 22,690 | 15.9 | 15.7 | 284,924 |
| product storage errorSignal | 6,709 | 10.5 | 10.2 | 53,422 |
| injection site bruisingSignal | 4,954 | 8.4 | 8.1 | 30,266 |
| injection site haemorrhageSignal | 4,136 | 6.9 | 6.7 | 19,874 |
| injection site painSignal | 11,254 | 4.8 | 4.7 | 33,255 |
| myalgiaSignal | 5,484 | 4.2 | 4.1 | 13,113 |
| drug dose omissionSignal | 4,929 | 3.9 | 3.8 | 10,327 |
| back painSignal | 5,658 | 3.2 | 3.1 | 8,219 |
| arthralgia | 4,143 | 1.3 | 1.2 | 244 |
| fatigue | 4,161 | 0.7 | 0.7 | 650 |
| off label use | 3,997 | 0.6 | 0.6 | 1,264 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.